Shares of InterMune Inc. shot up a whopping 144.5 percent Friday on a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for idiopathic pulmonary fibrosis (IPF) drug pirfenidone, a decision that came about two months earlier than expected and positions the company for a European approval in early 2011.